TABLE 2

Characteristics of Second-Dose Varicella Vaccination Reports Submitted to VAERS, 2006–2014

Report Characteristics4–6 y7–18 yAll Ages, 4–18 y
Varicella Vaccine Only, n (%)Varicella + Other Vaccines, n (%)Varicella Vaccine Only, n (%)Varicella + Other Vaccines, n (%)Total Reports, n (%)
Total reports75859072473550314 641
 Seriousa27 (4)223 (4)61 (2)183 (3)494 (3)
 Boysb324 (43)2956 (50)1040 (42)2262 (41)6582 (45)
 Girlsb341 (45)2884 (49)1375 (56)3198 (58)7798 (53)
Prespecified conditionsc
 Anaphylaxis8 (1)66 (1)10 (<1)26 (<1)110 (1)
 Meningitis0 (0)5 (<1)0 (0)2 (<1)7 (<1)
 Encephalitis0 (0)8 (<1)1 (<1)9 (<1)18 (<1)
 Cellulitis24 (3)334 (6)161 (7)209 (4)728 (5)
 Varicella117 (15)87 (1)107 (4)79 (1)390 (3)
 HZ15 (2)21 (<1)34 (1)37 (1)107 (1)
 Death0 (0)3 (<1)2 (<1)2 (<1)7 (<1)
  • a Includes death, life-threatening illness, hospitalization or prolongation of existing hospitalization, or permanent disability.

  • b Percentage of unknown sex ranged from 1% to 12%.

  • c Second-dose varicella vaccination reports of prespecified conditions classified as serious: anaphylaxis (n = 83, 75%), meningitis (n = 5, 71%), encephalitis (n = 16, 89%), cellulitis (n = 83, 11%), varicella (n = 6, 2%), HZ (n = 6, 6%); all deaths are serious reports. Of 83 serious reports of cellulitis, 52 (63%) reports were of cellulitis on the same limb on which the varicella vaccine was administered.